secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001842952-24-000005
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics amends Integral license for CTIM-76 after finding potential third-party patent conflict
--------------------------------------------------------------------------------

- Discovered third-party patents expiring Jan 2034 may cover CTIM-76; company believes it has defenses but may not prevail.
- Amendment reduces development milestones from $55M to $15M, sales milestones from $130M to $12.5M.
- Royalty reduced from 8–12% to flat 6% on net sales, starting no sooner than February 2034.
- License narrowed to only CTIM-76; company no longer obligated to reimburse Integral for research funding.
- Deal includes mutual releases and revised milestone triggers tied to Phase 1b/2, Phase 3, and marketing approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000005/0001842952-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000005/cntx-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001842952-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer